Compare DexCom, Inc. (DXCM) vs Nutanix Inc (NTNX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Nutanix Inc — how do they compare? DexCom, Inc. trades at $84.14 (market cap $31.86B), while Nutanix Inc trades at $74.59 (market cap $19.78B). The key difference: DexCom, Inc. is the larger of the two by market cap, and Nutanix Inc is trading nearer its 52-week high, DexCom, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Nutanix Inc for 17 Days on average.
| DXCM | NTNX | |
|---|---|---|
Market Cap | $31.86B | $19.78B |
Volume | 3,607,070 | 1,717,619 |
Sector | Health | Technology |
52-Week High | $92.34 | $73.42 |
52-Week Low | $54.84 | $34.41 |
Typical Hold Time | 62 Days | 17 Days |
Enterprise Value | $31.32B | $18.94B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.03, down 0.32% on the day, with strong fundamental performance including three consecutive quarterly EPS beats and robust 20.12% net income margin. The stock shows bearish technical signals with price near pivot point support at $84, while analyst consensus remains overwhelmingly positive with 81% buy ratings and $95.07 price target representing 13% upside potential. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
DXCM presents a compelling growth story with expanding profit margins and consistent earnings outperformance, though technical weakness and premium valuation create near-term headwinds. The company's leadership in continuous glucose monitoring and Type 2 diabetes market expansion provide long-term catalysts, while competition and reimbursement risks require monitoring.
Nutanix (NTNX) trades at $73.98, up 0.76% today, with a bullish technical signal from moving averages and strong recent earnings beats. The company reported robust profitability with a net income margin of 52.81% for 2026 and is recognized as a leader in multiple Gartner Magic Quadrant reports, highlighting its competitive strength in hybrid cloud infrastructure.
The outlook is positive with analyst consensus favoring a buy rating and a $76.11 price target, though risks include high valuation multiples like a 46.22 EV/EBITDA and negative ROE. Revenue growth and external storage expansion present opportunities, but investors should monitor execution against guidance and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Nutanix Inc
Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →
